Atypical association of H1 and H2 histamine receptors with signal transduction pathways during multistage mouse skin carcinogenesis

Inflammation Research

Volumn 46, Issue 8, 1997, Pages 292-298

  Fitzsimons, C ^a   Molinari, B ^b   Duran, H ^b   Palmieri, M ^c   Davio, C ^a   Cricco, G ^a   Bergoc, R ^a   Rivera, E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b LABORATORIO TANDAR   (Argentina)

^c Ciudad Universitaria   (Argentina)

Author keywords

cAMP; Histamine receptors; Inositol phosphates; Mouse skin carcinogenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ACETONE; CYCLIC AMP; HISTAMINE; HISTAMINE AGONIST; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE RECEPTOR; INOSITOL PHOSPHATE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL; CIMETIDINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; MEPYRAMINE; TIOTIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG HYDROLYSIS; FEMALE; MAST CELL; MOUSE; NONHUMAN; PHENOTYPE; SECOND MESSENGER; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR GROWTH; ANIMAL; CELL COUNT; CHEMICALLY INDUCED DISORDER; HYDROLYSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CELL COUNT; CIMETIDINE; CYCLIC AMP; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HYDROLYSIS; MAST CELLS; MICE; PHOSPHATIDYLINOSITOLS; PYRILAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H2; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 0030612654     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050190     Document Type: Article

References (38)

1. Slaga TJ. Mechanisms involved in two-stage carcinogenesis in mouse skin. In: Slaga TJ, editor. Mechanisms of tumor promotion, tumour promotion and skin carcinogenesis. Vol 2. Boca Raton: CRC Press, 1984:1-16.
2. 1 receptors. J Cell Biol 1990;11:121 1-5.
3. Davio C, Baldi A, Mladovan A, Cricco G, Fitzsimons C, Bergoc R, et al. Expression of histamine receptors in different cell lines derived from mammary gland and human breast carcinomas. Inflamm res 1995;44 Suppl 1:70-1.
4. Fischer S, Patrick KE, Patamalai B, Slaga TJ. Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes. Carcinogenesis 1990;11:991-6.
5. Ash ASF, Schild HV. Receptors mediating some actions of histamine. Br J Pharmacol Chemother 1986;27:427-39.
6. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharm Rev 1990;42:45-83.
7. Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995;66:413-63.
8. Mitsuhashi M, Payan DG. Functional diversity of histamine and histamine receptors. J Invest Dermatol 1992;98:85-11.
9. 2 histamine receptors in experimental carcinomas with an atypical coupling to signal transducers. Biochem Pharmacol 1995;50:91-6.
10. Cricco G, Davio CA, Fitzsimons CP, Engel N, Bergoc RM, Rivera ES. Hislamine as an autocrine growth factor in experimental carcinomas. Agents Actions 1994;43:17-20.
11. Aldaz CM, Conti CJ, Giménev IB, Slaga TJ, Klein-Szanto AJP. Cutaneous changes during prolonged application of 12-O-tetradecanoyl-phorbol-13-acetate on mouse skin and residual effects after cessation of treatment. Cancer Res 1985;45:2753-9.
12. Norrby K. Intradermal mast-cell secretion causing cutaneous mitogenesis. Virchows Arch Abt B Zellpath 1983;42:263-9.
13. 1 receptor agonist activity of a series of 2-phenylhistamine. 2-heteroarylhistamines and analogues. J Med Chem 1995;38:1287-94.
14. 2-receptor agonist. Part I, Pharmacology. Agents Actions 1977;7:31-7.
15. Freter CE, Lippman ME, Cheville A, Zinn S, Gelmann EP. Alterations in phosphoinositide metabolism associated with 17β-estradiol and growth factor treatment of MCF-7 breast cancer cells. Mol Endocrinol 1988;2:159-66.
16. Enerbäck L. Mast cells in rat gastrointestinal mucosa II: dye binding and metachromatic properties. Acta Pathol Microbiol Scand 1966;66:303-12.
17. Kitamura Y, Taguchi T, Yokoyama M, Tamai M, Yamatodani A, Watanabe T. Increase in histidine decarboxylase activity in mouse skin after application of tumor promoters. In: Fuyiki et al. editors. Cellular interactions by environmental tumor promoters. Japan Sci Soc Press, Tokyo 1984:327-34.
18. Watanabe T, Taguchi Y, Sasaki K, Tsuyama K, Kitamura Y. Increases of histidine decarboxylase activity in mouse skin after application of the tumor promoter tetradecanoyl phorbol acetate. Biochem Biophys Res Commun 1981;100:427-32.
19. Malaviya K, Morrison AR, Pentlamol AP. Histamine in human epidermal cells is induced by ultraviolet light injury. J Invest Dermatol 1996;1106:785-9.
20. Engel N, Cricco G, Davio C, Martin G, Croci M, Fitzsimons C, et al. Histamine regulates the expression of histidine decabroxylase in N-nitroso-N-methylurca (NMU)-induced mammary tumors in rats. Inflamm res 1996;45 Suppl 1:S64-5.
21. Davio C, Martin G, Cricco G, Fitzsimons C, Bergoc R, Rivera E. Role of histamine on growth and differentiation of the rat mammary gland. Agents Actions 1994;41:115-7.
22. Lemos B, Davio C, Gass H, Gonzalez P, Cricco G, Martin G, et al. Histamine receptors in human mammary gland, different benign lesions and mammary carcinomas. Inflamm res 1995;44 Suppl 1:68-9.
23. Fiore-Donati L, Debenedictis G, Chieco-Bianchi L. Development of mast cell reaction during chemical skin carcinogenesis of mouse. Nature (Lond) 1962;193:287-93.
24. Saiti H, Sanai Y, Nakamura H, Watanabe N, Ito T, Nagai Y. Enhancement of clonal proliferation of mouse mast cells by tumor-promoting phorbol ester. Cancer Res 1984;44:2110-4.
25. Rey BM de. Palmieri MA, Durán HA. Mast cell phenotypic changes in skin of mice during benzoyl peroxide-induced tumor promotion. Tumor Biol 1994;15:166-74.
26. 2 receptors. J Biol Chem 1989;264: 18356-62.
27. Klinker SF, Wenzelseifert K, Seifert R. G-protcin-coupled receptors in HL-60 human leukemia cells. Gen Pharmacol 1996;27:33-54.
28. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984;308:693-8.
29. Marks F, Gschwendt M. Protein kinase C and skin tumor promotion. Mutation Res 1995;333:161-72.
30. Stabel S, Parker PJ, Protein kinase C. Pharmacol Ther 1991;51:71-95.
31. Fleischman LF, Chahwala SB, Cantley L. Ras-transformed cells: altered levels of phosphatidylinositol 4,5 biphosphates and catabolites. Science 1986;231:407-10.
32. 1/S transition in mammary carcinoma cells. Endocrinology 1995;136:2513-19.
33. Quintanilla M, Brown K, Ramsden M, Baimain A. Carcinogen specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
34. Zarbl H, Sukumur S, Arthur A, Martin-Zanca D, Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 1985;315:382-5.
35. Blackmore PF, Oakes SG, Somers KD, Altered H, histamine receptor signaling in Balb/3T3 cells transformed by v-K-ras and v-H-ras oncogenes. Oncogene 1992;7:2053-7.
36. Kenakim T. Agonist-receptor efficacy II: agonist trafficking of receptors signals. TIPS 1995;16:232-8.
37. 2 receptor gene. NeuroReport 1996; 7:1293-6.
38. 2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase. Naunyn-Schmiedeberg's Arch Pharmacol 1996;353:123-9.